Bacterium (e.g., Bacillus, Etc.) Destroying Or Inhibiting Patents (Class 514/2.4)
-
Patent number: 9750844Abstract: The preset invention relates to a new method for wound healing, particularly in burns, comprising Epinecidin-1 (Epi-1) or Pardaxin (GE33), optionally in the incorporation into collagen.Type: GrantFiled: September 17, 2015Date of Patent: September 5, 2017Assignees: ACADEMIA SINICA, NATIONAL TAIWAN OCEAN UNIVERSITYInventors: Jyh-Yih Chen, Chang-Jer Wu, Han-Ning Huang
-
Patent number: 9708368Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: February 25, 2015Date of Patent: July 18, 2017Assignee: RQX PHARMACEUTICALS, INC.Inventors: Robert I. Higuchi, Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Prasuna Paraselli
-
Patent number: 9663563Abstract: The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.Type: GrantFiled: March 11, 2014Date of Patent: May 30, 2017Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Tomomi Nakatani, Koichi Saito
-
Patent number: 9649352Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.Type: GrantFiled: July 16, 2015Date of Patent: May 16, 2017Assignees: THE MEDICINES COMPANY, ABBVIE INC.Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
-
Patent number: 9630969Abstract: An N-alkyl tryptanthrin derivative, a preparation method for same, and an application thereof are provided. The structure of the derivative is as represented by formula I. The N-alkyl tryptanthrin derivative can serve as a highly active IDO inhibitor, for use in preparing a medicament for prevention and/or treatment of a disease having a pathological characteristic of an IDO-mediated tryptophan metabolic pathway.Type: GrantFiled: July 25, 2014Date of Patent: April 25, 2017Assignee: SHANGHAI TIN TSZ BIO VALLEY BIOLOGICAL ENGINEERING CO., LTDInventors: Hanpu Li, Chunxiang Kuang, Jianzhi Li
-
Patent number: 9603891Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.Type: GrantFiled: June 17, 2015Date of Patent: March 28, 2017Assignee: Chonnam National University HospitalInventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
-
Patent number: 9603893Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.Type: GrantFiled: April 27, 2016Date of Patent: March 28, 2017Assignee: Chonnam National University HospitalInventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
-
Patent number: 9604986Abstract: A process for preparation of compound of Formula (I) is disclosed. The application is also directed to polymorphic forms of the compound of formula (I).Type: GrantFiled: July 8, 2014Date of Patent: March 28, 2017Assignee: WOCKHARDT LIMITEDInventors: Ravikumar Tadiparthi, Bharat Dond, Satish Birajdar, Amol Kale, Vijaykumar Jagdishwar Patil
-
Patent number: 9603892Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.Type: GrantFiled: April 27, 2016Date of Patent: March 28, 2017Assignee: Chonnam National University HospitalInventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
-
Patent number: 9573974Abstract: Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided.Type: GrantFiled: January 8, 2014Date of Patent: February 21, 2017Assignee: LA SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA-SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Martin Fugére, Witold A. Neugebauer
-
Patent number: 9482666Abstract: The invention provides methods for identifying cell binding and/or lytic polypeptides that permit production of specific polypeptide therapeutics in a high throughput manner.Type: GrantFiled: November 1, 2012Date of Patent: November 1, 2016Assignee: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting for and on Behalf of Arizona State UniversityInventors: Valeriy Domenyuk, Chris Diehnelt, Stephen Johnston
-
Patent number: 9463214Abstract: The present invention relates to a peptide derived from the Helicobacter pylori ribosomal protein L1, and the use of this peptide an antibiotic. More specifically, the peptide is derived by making site-specific substitution mutations in a peptide consisting of amino acids 2-20 of the Helicobacter pylori ribosomal protein L1. The resulting peptide has both antibacterial activity and anti-inflammatory activity, but no cytotoxicity.Type: GrantFiled: July 1, 2015Date of Patent: October 11, 2016Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITYInventors: Yoon Kyung Park, Jong Kuk Lee
-
Patent number: 9440019Abstract: The invention relates to a sorption agent for removing endotoxins from a biological fluid, comprising a water-insoluble, porous carrier having a neutral hydrophobic surface wherein the surface of the carrier has an adsorptive coating made of polymyxin and albumin, wherein polymyxin and albumin are bonded to the surface of the carrier in a noncovalent manner. The invention further relates to a method for producing such a sorption agent. The sorption agent is used in extracorporeal blood purification, in particular in order to treat individuals, who have sepsis.Type: GrantFiled: June 22, 2011Date of Patent: September 13, 2016Assignee: Fresenius Medical Care Deutschland GmbHInventors: Dieter Falkenhagen, Stephan Harm, Jens Hartmann, Viktoria Weber
-
Patent number: 9352015Abstract: Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation.Type: GrantFiled: June 3, 2010Date of Patent: May 31, 2016Assignee: The Regents of the University of Colorado, a body corporateInventors: Robert S. Hodges, Ziqing Jiang
-
Patent number: 9328339Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: GrantFiled: May 1, 2014Date of Patent: May 3, 2016Assignee: Catalyst Biosciences, Inc.Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Patent number: 9320709Abstract: The invention provides compositions and methods for achieving storage stable aceclidine. The compositions preferably comprise aceclidine, a cycloplegic agent, a surfactant, a tonicity adjustor and optionally a viscosity enhancer and an antioxidant. The invention further provides methods for treating refractive errors of the eye with a storage stable aceclidine composition.Type: GrantFiled: June 18, 2015Date of Patent: April 26, 2016Assignee: Presbyopia Therapies LLCInventors: Gerald Horn, Lee Nordan
-
Patent number: 9278121Abstract: The present invention encompasses methods for treating an infection and/or treating or reducing inflammation through the administration of a therapeutically effective amount of a peptide to a subject in need thereof. In some aspects, the peptide is a Helicobacter pylori-derived peptide, such as an HPA3NT3 peptide and the infection is a bacterial infection.Type: GrantFiled: March 14, 2013Date of Patent: March 8, 2016Assignees: The Board of Trustees of the University of Arkansas, Chosun UniversityInventors: Peter I. Song, Cheryl Armstrong, Sunhyo Ryu, Yoonkyung Park, Kyung-soo Hahm
-
Patent number: 9271958Abstract: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.Type: GrantFiled: July 23, 2014Date of Patent: March 1, 2016Assignee: Nestec S.A.Inventors: Magali Faure, Florence Rochat, Denis Breuille, Irene Corthesy Theulaz
-
Patent number: 9265709Abstract: The present invention relates to compositions comprising peptides with antidandruff activity. The invention also relates to the use of these peptides as antidandruff agents, or in methods for treating dandruff.Type: GrantFiled: December 17, 2010Date of Patent: February 23, 2016Assignee: L'OREALInventor: Henri Samain
-
Patent number: 9243040Abstract: The invention provides polymers comprising Formula I: wherein monomer is a repeating unit comprising 2, 3, 4, 5, 6 or 7 carbon atoms and the monomers are linked together through amide or ester bonds; n is about 6 to about 1000; and Linker is an optionally substituted carbon chain that is optionally interrupted by moieties such as oxygen, nitrogen, sulfur, phosphorus, or silicon. Charge is a moiety having a positive or negative charge on a heteroatom, such as nitrogen, oxygen, phosphorus, or sulfur; where the Linker separates the monomer and the Charge by at least six linear atoms. The invention also provides methods of preparing the polymers and the copolymers and methods of using the polymers and copolymers, for example, as drug delivery systems, as membrane penetrating peptides, and as therapeutic agents.Type: GrantFiled: November 30, 2011Date of Patent: January 26, 2016Assignee: The Board of Trustees of the University of IllinoisInventors: Jianjun Cheng, Hua Lu
-
Patent number: 9217015Abstract: The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.Type: GrantFiled: July 18, 2011Date of Patent: December 22, 2015Assignee: S&T Global Inc.Inventors: Zhuang Su, Zhennian Huang, Zhengyu Long, Suizhou Yang
-
Patent number: 9192578Abstract: The present invention includes compositions and methods of making a modified release pharmaceutical formulation and a method of preparation for the embedding of modified release multi-particulates into a polymeric or wax-like matrix. The modified release multi-particulates comprise an effective amount of a therapeutic compound having a known or desired drug-release profile. Modified release multi-particulates may include a polymeric coat or may be incorporated into particle or core material. The polymer matrix comprises a thermoplastic polymer or lipophilic carrier or a mixture thereof that softens or melts at elevated temperature and allows the distribution of the modified release multi-particulates in the polymer matrix during thermal processing. Formulation compounds and processing conditions are selected in a manner to preserve the controlled release characteristics and/or drug-protective properties of the original modified release multi-particulates.Type: GrantFiled: August 20, 2009Date of Patent: November 24, 2015Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: James W. McGinity, Sandra U. Schilling
-
Patent number: 9175042Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.Type: GrantFiled: October 11, 2011Date of Patent: November 3, 2015Assignee: Allergan, Inc.Inventors: Michael E. Garst, William Carling, David Scowen, Michael E. Stern, Christopher S. Schaumburg
-
Patent number: 9161990Abstract: The present invention relates to a compound of formula I: wherein x is in the range of from about 1 to about 2. The invention also relates to pharmaceutical compositions containing such compounds; processes for preparing such compounds; and methods of using such compounds to, for example, treat a bacterial infection.Type: GrantFiled: March 6, 2014Date of Patent: October 20, 2015Assignee: Theravance Biopharma Antibiotics IP, LLCInventors: Weijiang Zhang, Ronnie Cheung, Dimitar Filipov, Jack Green, Junning Lee
-
Patent number: 9133238Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: GrantFiled: January 7, 2009Date of Patent: September 15, 2015Assignee: Rapid Pathogen Screeening, Inc.Inventors: Johannes Gerhardus Maria Bolscher, Arie Van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem Van't Hof, Kamran Nazmi, Petronella Adriana Maria Van Den Keijbus
-
Patent number: 9107917Abstract: Provided are methods for treating a mammal undergoing sepsis, or at risk for sepsis. Also provided are methods of preventing or treating a physiological effect of sepsis in a mammal. Additionally provided are methods of inhibiting an inflammatory response in a mammal. Further provided is the use of an ?2A-adrenergic antagonist for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal, and the use of an ?2A-adrenergic antagonist for the treatment of a mammal having sepsis or at risk for sepsis.Type: GrantFiled: May 11, 2006Date of Patent: August 18, 2015Assignee: The Feinstein Institute For Medical ResearchInventor: Ping Wang
-
Patent number: 9107443Abstract: The present invention relates to liquid nisin compositions having a high anti-microbial activity. The invention further relates to a method for preparing the liquid nisin compositions as well as their use as a preservative in food products.Type: GrantFiled: August 12, 2009Date of Patent: August 18, 2015Assignee: DSM IP ASSETS B.V.Inventors: Johannes Martinus Jacobus Visser, Ben Rudolf De Haan
-
Patent number: 9045563Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.Type: GrantFiled: July 3, 2008Date of Patent: June 2, 2015Assignee: PHARIS BIOTECH GMBHInventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Publication number: 20150140186Abstract: The protection of low-acid, high moisture and/or high water activity processed food products against outgrowth of Clostridium botulinum. It was surprisingly found that combinations of propionic acid and/or a salt thereof with nisin are very effective in preventing Clostridium botulinum outgrowth. In certain embodiments, cinnamic acid and/or a salt thereof can be added to these combinations to give particularly good results. These combinations provide a preservative system that is particularly effective against Clostridium botulinum outgrowth. The use of these preservative systems in food products that are conductive to Clostrisium botulinum outgrowth. The food products including these preservative systems and the methods of producing them.Type: ApplicationFiled: November 13, 2014Publication date: May 21, 2015Applicant: PURAC BIOCHEM B.V.Inventors: Arne Olav Sliekers, Johanna Gerarda Elisabeth Wijman, Kumar Saurabh
-
Publication number: 20150141324Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.Type: ApplicationFiled: August 31, 2012Publication date: May 21, 2015Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Publication number: 20150132343Abstract: A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be HIV.Type: ApplicationFiled: November 10, 2014Publication date: May 14, 2015Inventor: Luc Montagnier
-
Publication number: 20150133365Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: ApplicationFiled: January 23, 2015Publication date: May 14, 2015Applicant: ANGES MG, INC.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Patent number: 9029318Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), YDYSFY (SEQ ID NO: 63), FDYNFY (SEQ ID NO: 3), FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7) and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and moss or any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.Type: GrantFiled: September 23, 2009Date of Patent: May 12, 2015Assignee: Tel Hashomer Medical Research, Infrastructure and Services Ltd.Inventors: Amir Zlotkin, Hen Kestenboim
-
Publication number: 20150126433Abstract: Described herein are novel methods and kits for treating mycobacterium infections with KGF. The methods include administering an amount of KGF effective to treat the mycobacterium infection. The mycobacterium may be M. tuberculosis, drug resistant strains of M. tuberculosis, or atypical mycobacterium. The infections may be pulmonary infections. The method and kit may further include additional antimicrobial compounds effective against mycobacterium infections.Type: ApplicationFiled: April 25, 2013Publication date: May 7, 2015Inventors: Francis X. McCormack, Rajamouli Pasula
-
Publication number: 20150126434Abstract: A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier.Type: ApplicationFiled: May 23, 2013Publication date: May 7, 2015Applicant: TOAGOSEI CO., LTD.Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida
-
Publication number: 20150125503Abstract: The invention provides improvements of lantibiotics useful for reducing the numbers of microbes or the reproduction of microbes in or on subjects or objects. One embodiment of the invention provides variants of antibiotics wherein the amino acid at position (1) is changed to Ile or Gly, the amino acid at position (4) is changed to an Ala, the amino acid at position (4) is removed, the amino acid at position (5) is changed to an Ala, or wherein, as in the case of MU1140, the amino acid at position (13) is Arg, the Arg at position (13) is substituted with Asp, or combinations of two or more these changes or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 22, 2013Publication date: May 7, 2015Inventors: Jeffrey D. Hillman, James Leif Smith, Shawanda R. Wilson-Stanford
-
Publication number: 20150118208Abstract: The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCR? cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.Type: ApplicationFiled: May 2, 2013Publication date: April 30, 2015Inventors: Thomas M. Schmitt, Philip D. Greenberg
-
Patent number: 9018158Abstract: The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.Type: GrantFiled: June 3, 2010Date of Patent: April 28, 2015Assignee: Algipharma ASInventors: Edvar Onsoyen, Rolf Myrvold, Arne Dessen, David Thomas, Timothy Rutland Walsh
-
Patent number: 9017692Abstract: Provided herein is a biologically pure culture of Paenibacillus thiaminolyticus, identified as OSY-SE, as well as an antimicrobial agent isolated and/or purified from the culture having any one of SEQ ID NOs:1-3 and 64-66. The disclosure also provides compositions and articles of manufacture comprising an antimicrobial agent and/or the bacterial cell of Paenibacillus thiaminolyticus, identified as OSY-SE. Further provided are methods of use, including methods of affecting microbial activity, methods of inhibiting growth and/or proliferation of a microbe, methods of treating a condition or disease associated with the presence of a microbe, and methods of treating a microbial infection in a subject comprising contacting a microbial cell with at least one active agent of SEQ ID NOs:1-3 and 64-66 and/or the bacterial cell Paenibacillus thiaminolyticus, identified as OSY-SE. The disclosure also provides the biosynthetic machinery (e.g.Type: GrantFiled: December 5, 2012Date of Patent: April 28, 2015Assignee: Ohio State Innovation FoundationInventors: Ahmed E. Yousef, Yaoqi Guo, En Huang, Chunhua Yuan, Liwen Zhang
-
Patent number: 9012396Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.Type: GrantFiled: January 9, 2013Date of Patent: April 21, 2015Assignee: Yissum Research Development Company of The Hebrew University of JerusalemInventor: Saul Yedgar
-
Patent number: 9012521Abstract: An object of the present invention is to provide a gel containing pyrroloquinoline quinone that is capable of easily forming a gel near room temperature and is useful even in the food sector, and a method for producing the gel. According to the present invention, there is provided a gel containing pyrroloquinoline quinone that uses pyrroloquinoline quinone itself as a gelling agent and a method for producing the gel by adding a salt of pyrroloquinoline quinone to water and subsequently adjusting the temperature or the pH to reduce solubility.Type: GrantFiled: August 9, 2011Date of Patent: April 21, 2015Assignee: Mitsubishi Gas Chemical Company, Inc.Inventors: Tsuyoshi Mikekado, Kazuto Ikemoto, Hajime Shimizu
-
Publication number: 20150104492Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.Type: ApplicationFiled: October 3, 2014Publication date: April 16, 2015Inventors: Alison McDermott, Marialuisa Mangoni
-
Patent number: 9006392Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: GrantFiled: February 1, 2011Date of Patent: April 14, 2015Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Patent number: 8999922Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: February 15, 2013Date of Patent: April 7, 2015Assignee: RQX Pharmaceuticals, Inc.Inventors: Robert I. Higuchi, Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Prasuna Paraselli
-
Publication number: 20150093370Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Inventors: Yoram SHECHTER, Matityahu FRIDKIN
-
Publication number: 20150087579Abstract: A novel antimicrobial peptide includes at least eight successive amino acids, the peptide exhibiting a sequence having the following formula: Ter1-X1-B1-X2-B2-X3-Z1-Z2-X4-Ter2. The peptide can moreover also have modified termini. The peptide is believed to be effective for the treatment or prevention of inflammatory and infectious diseases that are caused by microorganisms such as bacteria or fungi.Type: ApplicationFiled: March 7, 2013Publication date: March 26, 2015Applicant: ROBERT BOSCH GENSELLSCHAFT FÜR MEDIZINISCHE FORSCHUNG MBHInventors: Eduard Stange, Bjoern Schroeder, Jan Wehkamp
-
Publication number: 20150087581Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.Type: ApplicationFiled: December 8, 2014Publication date: March 26, 2015Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, Koteswara Rao Vemula, Leena Khare Satyam, Krishnaprasad Subbarao, K. Rajeev Shrimali, Sreenivas Kandepu
-
Publication number: 20150087580Abstract: Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.Type: ApplicationFiled: November 26, 2014Publication date: March 26, 2015Applicant: Carrus Capital CorporationInventors: Timothy J. KRIEGER, Patricia J. McNicol
-
Publication number: 20150087582Abstract: Compositions comprising iron-sequestering glycoproteins, chelating agents, stabilizing agents, binding agents, surfactants, fluorides, antimicrobials and a pH adjuster or buffer for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. Additionally, the invention offers an efficient method of delivering the formulated composition containing a PEGylated or fluorinated iron-sequestering glycoprotein and one or two chelating agents or chelating agents alone using either a liposomal or a nanoparticle delivery system.Type: ApplicationFiled: June 27, 2012Publication date: March 26, 2015Inventors: Karen LoVetri, Srinivasa Madhyastha, Nandadeva Yakandawala, Purushottam V. Gawande, Gord Froehlich
-
Publication number: 20150080291Abstract: Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of KPV or KdPT that exhibit antimicrobial activity. In particular, the peptides of this invention provide enhanced anti-microbial activity over the base tri-peptides, lysine-proline-valine and lysine-d-proline-tyrosine. The disclosed peptides have the general formula of C12-18 lipid-KXZ-NH2i wherein K is lysine; X is proline, d-proline, histidine or arginine; Z is optional and if present Z is valine, threonine, alanine or leucine; and the terminal COOH is NH2 amidated. The C12-18 lipid is preferably the lipid moiety of lauric acid (C12), myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), or stearic acid (C18). The invention is further related to methods of using of these peptides to treat various insults, inflammations or bacterial infections affecting the skin and other related mucosal body surfaces such as the oral cavity.Type: ApplicationFiled: March 7, 2013Publication date: March 19, 2015Inventors: Lijuan Zhang, Robin Carmichael